retatrutide clinical trials weight loss results 🚨 BREAKING: Shows “Bariatric-Level” in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most 📈 RETATRUTIDE PHASE 3 RESULTS:

Doctors diagnose BED by looking for specific patterns, such as: Eating unusually large amounts of food in a short time (usually within 2 hours) Feeling out of control during eating episodes Experiencing these episodes at least once a week for three months Feeling distressed about the binge eating Not regularly purging or engaging in compensatory behaviors like excessive exercise or laxative misuse after binges (which may veer towards bulimia) Self-screening tools like the Binge Eating Scale may help you assess the severity of your binge eating behaviors and track your improvement during treatment

For tirzepatide (Zepbound) Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that at maximal doses, the percent of individuals reporting side effects were as follows: Nausea 31.0% Diarrhea 23.0% Vomiting 12.2% Constipation 11.7% Bettge and colleagues conducted a study published in Diabetes, Obesity, and Metabolism in 2017 that showed that individuals who were taking metformin while taking a GLP-1 were more likely to have side effects, especially nausea and vomiting

Can You Stop GLP-1s After Reaching Your Goal Every patients journey on GLP-1s is unique

One thing to keep in mind, though, is that it can be hard to gauge when menopause is coming if you're on the pill.)

Mild-to-moderate gastrointestinal adverse events were more frequent with semaglutide (82.2% versus 53.9%)